A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 2 Virus Vaccine, rHPIV2 15C/948L/Δ1724 Lot PIV2#109C, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV2-Seropositive Children 15 to 59 Months of Age, and HPIV2-Seronegative Infants and Children 6 to 59 Months of Age

Human parainfluenza virus type 2 (HPIV2) can result in severe respiratory illness in infants and young children. This study will test the safety of and immune response to an HPIV2 vaccine aimed at infants and children.

开始日期2010-06-01

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与 Live attenuated human parainfluenza virus type 2 vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床结果

登录后查看更多信息

100 项与 Live attenuated human parainfluenza virus type 2 vaccine(National Institute of Allergy & Infectious Diseases) 相关的转化医学

登录后查看更多信息

100 项与 Live attenuated human parainfluenza virus type 2 vaccine(National Institute of Allergy & Infectious Diseases) 相关的专利（医药）

登录后查看更多信息

项与 Live attenuated human parainfluenza virus type 2 vaccine(National Institute of Allergy & Infectious Diseases) 相关的文献（医药）

2023-04-18·Journal of the Pediatric Infectious Diseases Society

Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children

Article

作者: Schaap-Nutt, Anne ; Collins, Peter L ; Buchholz, Ursula J ; Karron, Ruth A ; Wanionek, Kimberli ; Herbert, Kristi ; Schmidt, Alexander C

AbstractWe conducted a phase I clinical trial of the live-attenuated recombinant human parainfluenza virus type 2 (HPIV2) vaccine candidate rHPIV2-15C/948L/∆1724 sequentially in adults, HPIV2-seropositive children, and HPIV2-seronegative children, the target population for vaccination. rHPIV2-15C/948L/∆1724 was appropriately restricted in replication in adults and HPIV2-seropositive children but was overattenuated for HPIV2-seronegative children.

2021-12-01·iScience2区 · 综合性期刊

Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2

2区 · 综合性期刊

ArticleOA

作者: Ito, Mutsumi ; Kawaoka, Yoshihiro ; Ono, Ryoichi ; Yamayoshi, Seiya ; Eguchi, Asami ; Fukumura, Masayuki ; Nosaka, Tetsuya ; Maeda, Mitsuyo ; Ohtsuka, Junpei ; Imai, Masaki ; Kataoka, Yosky ; Maemura, Tadashi

We developed an intranasal vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the replication-incompetent human parainfluenza virus type 2 (hPIV2) vector BC-PIV, which can deliver ectopic gene as stable RNA and ectopic protein on the envelope. BC-PIV expressing the full-length prefusion-stabilized spike gene (K986P/V987P) of SARS-CoV-2, S-2PM, possessed a corona-like viral envelope. Intranasal vaccination of mice with BC-PIV/S-2PM induced high levels of neutralizing immunoglobulin G (IgG) and mucosal IgA antibodies against the spike protein. Although BC-PIV showed hemagglutinating activity, BC-PIV/S-2PM lacked such activity, in accordance with the presence of the massive spike protein on the viral surface. Furthermore, single-dose intranasal vaccination of hamsters with BC-PIV/S-2PM completely protected the lungs from SARS-CoV-2 at 11-week post-immunization, and boost vaccination two weeks before the challenge conferred virtually complete protection of the nasal turbinates against SARS-CoV-2. Thus, this chimeric hPIV2/spike intranasal vaccine is a promising vaccine candidate for SARS-CoV-2 to curtail virus transmission.

2017-02-01·Journal of Allergy and Clinical Immunology1区 · 医学

Restrictive IL-10 induction by an innocuous parainfluenza virus vector ameliorates nasal allergy

1区 · 医学

Letter

作者: Isono, Kana ; Hasegawa, Chisami ; Yamagiwa, Akisa ; Kakeda, Masato ; Mizutani, Kento ; Kawano, Mitsuo ; Nosaka, Tetsuya ; Matsushima, Yoshiaki ; Inada, Hiroyasu ; Yamanaka, Keiichi ; Mabuchi, Tomotaka ; Mizutani, Hitoshi ; Yamazaki, Hidetoshi ; Gabazza, Esteban C ; Nakanishi, Takehisa ; Kondo, Makoto ; Habe, Koji ; Okada, Karin

This article describes the therapeutic application of IL-10 in vivo by using recombinant human parainfluenza type 2 virus (rhPIV2) vector.The inflammatory cytokine levels in the nasal secretion were significantly reduced in rhPIV2/IL-10 treated mice.The immunomodulatory effects of vaccination in the distant lymphoid tissues, and evaluated cytokines production of lymphocytes from cervical lymph nodes and spleen are discussed.

100 项与 Live attenuated human parainfluenza virus type 2 vaccine(National Institute of Allergy & Infectious Diseases) 相关的药物交易

登录后查看更多信息